X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA AJANTA PHARMA PLETHICO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x -1.1 20.7 - View Chart
P/BV x 0.0 4.8 0.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
AJANTA PHARMA
Mar-18
PLETHICO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3951,818 21.7%   
Low Rs311,106 2.8%   
Sales per share (Unadj.) Rs604.4239.5 252.4%  
Earnings per share (Unadj.) Rs32.552.8 61.5%  
Cash flow per share (Unadj.) Rs51.359.5 86.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6230.0 205.9%  
Shares outstanding (eoy) m34.0888.77 38.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.46.1 5.8%   
Avg P/E ratio x6.627.7 23.7%  
P/CF ratio (eoy) x4.224.6 16.9%  
Price / Book Value ratio x0.56.4 7.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,262129,782 5.6%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m1,5963,765 42.4%   
Avg. sales/employee Rs ThNM3,128.4-  
Avg. wages/employee Rs ThNM554.0-  
Avg. net profit/employee Rs ThNM689.7-  
INCOME DATA
Net Sales Rs m20,59821,258 96.9%  
Other income Rs m386242 159.9%   
Total revenues Rs m20,98421,499 97.6%   
Gross profit Rs m2,8186,584 42.8%  
Depreciation Rs m642596 107.8%   
Interest Rs m1,5934 38,858.5%   
Profit before tax Rs m9696,226 15.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,539 -9.0%   
Profit after tax Rs m1,1074,686 23.6%  
Gross profit margin %13.731.0 44.2%  
Effective tax rate %-14.324.7 -57.8%   
Net profit margin %5.422.0 24.4%  
BALANCE SHEET DATA
Current assets Rs m18,87712,236 154.3%   
Current liabilities Rs m11,8963,461 343.8%   
Net working cap to sales %33.941.3 82.1%  
Current ratio x1.63.5 44.9%  
Inventory Days Days3660 59.7%  
Debtors Days Days19884 234.2%  
Net fixed assets Rs m9,86111,140 88.5%   
Share capital Rs m341177 192.6%   
"Free" reserves Rs m12,33120,237 60.9%   
Net worth Rs m16,13920,414 79.1%   
Long term debt Rs m4,70610 46,592.1%   
Total assets Rs m33,14624,486 135.4%  
Interest coverage x1.61,519.4 0.1%   
Debt to equity ratio x0.30 58,934.3%  
Sales to assets ratio x0.60.9 71.6%   
Return on assets %8.119.2 42.5%  
Return on equity %6.923.0 29.9%  
Return on capital %12.330.5 40.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40211,667 37.7%   
Fx outflow Rs m3,1841,616 197.1%   
Net fx Rs m1,21910,052 12.1%   
CASH FLOW
From Operations Rs m2,4372,854 85.4%  
From Investments Rs m-6,265-2,604 240.6%  
From Financial Activity Rs m2,490-2 -124,505.0%  
Net Cashflow Rs m-1,337248 -539.0%  

Share Holding

Indian Promoters % 82.7 73.8 112.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 1.6 277.4%  
FIIs % 5.5 7.6 72.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.0 44.1%  
Shareholders   10,665 20,968 50.9%  
Pledged promoter(s) holding % 85.7 4.4 1,953.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Sensex Ends 77 Points Higher(Closing)

Indian share markets witnessed buying interest during closing hours and ended on a positive note. Gains were seen in the metal sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS